Immatics NV (FRA:4A3) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4A3 Immatics NV FRA:4A3
61 GF Score
Price €8.20
GF Value €2.81
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Immatics NV SpecialCharges?

Special Charges only applies to banks.

FRA:4A3
61GF Score
Immatics NV FRA:4A3
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Immatics NV (FRA:4A3) Overvalued in 2026?

Based on GuruFocus' analysis, Immatics NV stock appears to be overvalued. The current stock price of €8.20 is trading 191.8% above its estimated GF Value™ of €2.81. GuruFocus considers Immatics NV to be Significantly Overvalued.

Key valuation signals for FRA:4A3:

  • SpecialCharges:
  • GF Value™: €2.81 vs. price of €8.20 (191.8% above fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the FRA:4A3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Immatics NV Business Description

Other Exchanges IMTX:USA
Address Paul-Ehrlich-Strasse 15, Tubingen, BW, DEU, 72076
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
61GF Score

Get the complete analysis for FRA:4A3

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.20
Price
€2.81
GF Value